RESUMEN
The aim of the article is presentation of the testing methodology and results of examination the probabilistic model of the measurement process. The case study concerns the determination of the risk of an incorrect decision in the assessment of the compliance of products by measurement. Measurand is characterized by the generalized Rayleigh distribution. The model of the measurement process was tested in parallel mode by six risk metrics. An undesirable effect in the reconstruction building block of the model was detected, consisting in the distortion of probability distribution at the edges of the measuring range. The paper gives guidelines on how to use the model, to obtain the analytical risk assessment consistent with the results of the Monte Carlo method. The study can be useful in product quality control, test design, and fault diagnosis.
RESUMEN
BACKGROUND: Atopic dermatitis (AD) is one of the most common skin diseases in dogs. Monitoring the progress of treatment may include assessment of lesion severity by use of Canine Atopic Dermatitis Extent and Severity Index (CADESI), assessment of pruritus and measurement of biophysical parameters of the skin. HYPOTHESIS: This study aimed to assess changes in transepidermal water loss (TEWL) during 12 weeks of treatment with lokivetmab and its correlation with the CADESI-04 and the severity of pruritus. ANIMALS: Ten client-owned dogs with canine AD. METHODS AND MATERIALS: The animals were administered lokivetmab three times at four week intervals. Pruritus and CADESI-04 were assessed, and TEWL was measured at six body regions, on Day 0 and repeated at weeks 4, 8 and 12. RESULTS: There was a significant decrease in the CADESI-04 score, the severity of pruritus and the mean TEWL between baseline and each of the time points. TEWL also decreased in the majority of body sites examined. Significant correlations between the CADESI-04 and mean TEWL (r = 0.519, P = 0.0003), and between pruritus severity and mean TEWL (r = 0.517, P = 0.0003), were found. CONCLUSIONS AND CLINICAL SIGNIFICANCE: Overall TEWL decreased during lokivetmab treatment but not at all body sites. If TEWL is used to assess the effectiveness of a treatment, a mean TEWL score should be calculated from several areas of the body.
